Synalar label

Synalar

Synalar Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

SYNALAR® Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

SYNALAR® (fluocinolone acetonide) Topical Solution 0.01% is intended for topical administration. The active component is the corticosteroid fluocinolone acetonide, which has the chemical name pregna-1,4-diene-3,20-dione,6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis (oxy)]-,(6α,11β,16α)-. It has the following chemical structure:

Chemical Structure

SYNALAR® Solution contains fluocinolone acetonide 0.1 mg/mL in a water-washable base of citric acid and propylene glycol.

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Synalar Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Synalar Manufacturers

  • Medimetriks Pharmaceuticals, Inc.
    Synalar | Medimetriks Pharmaceuticals, Inc.
    No Recall

    Synalar | Medimetriks Pharmaceuticals, Inc.

    Synalar | Medimetriks Pharmaceuticals, Inc.

    SYNALAR® Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

    Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  • Medimetriks Pharmaceuticals, Inc.
    Synalar | Medimetriks Pharmaceuticals, Inc.
    No Recall

    Synalar | Medimetriks Pharmaceuticals, Inc.

    Synalar | Medimetriks Pharmaceuticals, Inc.

    SYNALAR® Ointment is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

    Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation.

    If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  • Medimetriks Pharmaceuticals, Inc.
    Synalar | Medimetriks Pharmaceuticals, Inc.
    No Recall

    Synalar | Medimetriks Pharmaceuticals, Inc.

    Synalar | Medimetriks Pharmaceuticals, Inc.

    SYNALAR® Solution is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

    Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions.

    If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

  • Medimetriks Pharmaceuticals, Inc.
    Synalar | Medimetriks Pharmaceuticals, Inc.
    No Recall

    Synalar | Medimetriks Pharmaceuticals, Inc.

    Synalar | Medimetriks Pharmaceuticals, Inc.

    SYNALAR® Cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

    Occlusive dressing may be used for the management of psoriasis or recalcitrant conditions. Some plastic films may be flammable and due care should be exercised in their use. Similarly, caution should be employed when such films are used on children or left in their proximity, to avoid the possibility of accidental suffocation.

    If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Login To Your Free Account